How to Get Dayvigo (Lemborexant) in Utah

What Is Dayvigo and Why It Differs From Older Sleep Drugs

Dayvigo is an orexin receptor antagonist, not a benzodiazepine or Z-drug. It blocks both OX1R and OX2R receptors, which quiets the brain's wakefulness-promoting orexin system rather than broadly suppressing the central nervous system [1]. That mechanism matters clinically: traditional agents such as zolpidem or triazolam enhance GABA-A activity globally, carrying risks of respiratory depression, dependence, and next-morning impairment at therapeutic doses.

The FDA approved lemborexant on December 20, 2019, at doses of 5 mg and 10 mg for adults with chronic insomnia disorder [2]. The approved label states: "The recommended dose is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to 10 mg based on clinical response and tolerability" [2].

In SUNRISE-1 (N = 291), patients randomized to lemborexant 10 mg showed a mean reduction in subjective sleep onset latency of 18.8 minutes vs. 8.5 minutes for placebo at month 1 (P<0.001), and sleep efficiency on polysomnography improved by 10.4 percentage points vs. 4.5 percentage points for placebo at the same timepoint [3]. A separate 12-month safety extension from the SUNRISE-2 trial (N = 949) confirmed no rebound insomnia signal and no evidence of physiologic withdrawal after abrupt discontinuation [4].

Because lemborexant does not produce the same degree of respiratory depression as benzodiazepines, it may be preferred for older adults or those with mild obstructive sleep apnea, though prescribers should still exercise caution in patients with severe sleep-disordered breathing [1]. The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for chronic insomnia lists orexin receptor antagonists as an evidence-supported pharmacologic option, and the 2023 update maintained that position [5].

Schedule IV classification means every prescription requires a valid DEA-registered prescriber and cannot be called in to a pharmacy without proper authorization. Refills are permitted up to five times within six months under federal Schedule IV rules [6].

Utah Telehealth Rules That Make Online Prescribing Legal

Utah permits telehealth prescribing of Schedule IV controlled substances provided the prescriber holds an active Utah medical license, establishes a valid patient-provider relationship during the visit, and complies with the Utah Controlled Substances Act (Utah Code § 58-37) [7]. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires at least one in-person evaluation before prescribing a controlled substance via the internet, but the DEA's February 2023 proposed rules created exceptions for audio-visual telehealth visits conducted by DEA-registered practitioners [8].

In practical terms, a Utah-licensed physician, nurse practitioner, or physician assistant can legally prescribe lemborexant after a synchronous (live video) consultation without a prior in-person visit, as long as the provider complies with DEA and Utah state requirements. Utah's Nurse Practice Act (Utah Code § 58-31b) allows certified nurse practitioners to prescribe Schedule IV substances independently within their scope of practice [9]. Physician assistants in Utah may prescribe Schedule IV medications under a delegation agreement with a supervising physician [10].

HealthRX telehealth visits for insomnia use a standardized intake that documents sleep history, Epworth Sleepiness Scale score, prior treatment trials, contraindications, and current medications. That documentation satisfies the "valid medical purpose" standard required by the Controlled Substances Act.

Step-by-Step: Getting a Dayvigo Prescription in Utah

Getting lemborexant in Utah follows a predictable sequence regardless of whether the visit is in-person or online.

Step 1. Complete a sleep-focused intake. The provider will ask about insomnia duration (must be at least 3 months to meet DSM-5 chronic insomnia criteria), sleep diary findings if available, prior medication trials (e.g., trazodone, zolpidem, eszopiclone, melatonin), and comorbidities such as depression, anxiety, or sleep apnea [11].

Step 2. Rule out contraindications. Lemborexant is contraindicated in patients with narcolepsy. It carries a pregnancy Category warning and should not be used in patients <18 years old, as safety has not been established in pediatric populations [2]. Drug interactions with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase lemborexant plasma concentrations substantially and require dose reduction to 5 mg maximum [2].

Step 3. Labs and baseline assessment. No mandatory laboratory panel is required before initiating lemborexant under the FDA label. However, HealthRX providers routinely order a baseline hepatic function panel because lemborexant is hepatically metabolized via CYP3A4, and moderate-to-severe hepatic impairment requires dose reduction or avoidance [2]. A thyroid-stimulating hormone (TSH) test is also ordered when clinical presentation suggests secondary insomnia from thyroid dysfunction [12].

Step 4. Prescription transmission. The provider transmits an electronic prescription (e-prescribe) to a Utah-licensed pharmacy. Federal law requires Schedule IV prescriptions to be transmitted electronically in most cases under DEA Electronic Prescribing for Controlled Substances (EPCS) regulations [6].

Step 5. Insurance adjudication or cash-pay. Most commercial plans in Utah list Dayvigo on Tier 3 or Tier 4 of their formularies, triggering prior authorization. Cash-pay pricing through GoodRx-affiliated pharmacies in Salt Lake City ranges from approximately $280 to $340 for a 30-tablet supply of 10 mg as of mid-2025. Eisai's patient assistance program, Dayvigo Direct, offers eligible uninsured patients savings of up to $150 per prescription [13].

Step 6. Pickup or mail delivery. Utah retail pharmacies with Dayvigo in stock include major chains (Smith's, Walgreens, CVS, Harmons). Most can fulfill a new prescription within 24 to 48 hours if stock is available. Mail-order pharmacies licensed in Utah can ship to any Utah address and typically deliver within 3 to 5 business days.

Prior Authorization in Utah: What Payers Require

Prior authorization (PA) is the single biggest delay in accessing Dayvigo for Utah patients with commercial insurance. Understanding what documents payers want cuts approval time from weeks to days.

Most Utah commercial health plans (SelectHealth, PEHP, Regence BlueCross BlueShield of Utah, and others) base their PA criteria on InterQual or proprietary criteria that typically demand [14]:

• A diagnosis of chronic insomnia disorder (ICD-10: G47.00) documented for at least 3 months.
• At least one documented trial of a generic insomnia agent at adequate dose and duration. Payers most commonly require a trial of zolpidem (5 mg or 10 mg for at least 4 weeks) or trazodone (50 to 100 mg for at least 4 weeks).
• Documentation that Cognitive Behavioral Therapy for Insomnia (CBT-I) was offered, attempted, or declined. The AASM designates CBT-I as first-line treatment for chronic insomnia [5].
• Absence of contraindications as listed in the FDA label.
• Prescriber attestation that the patient has been counseled on next-morning driving impairment risk.

Utah Medicaid (both fee-for-service and managed care plans administered through Centene and Molina) does not cover lemborexant on its preferred drug list as of the 2025 Medicaid Drug Utilization Review Board cycle. Patients on Medicaid should ask their provider about suvorexant (Belsomra), which occupies a similar mechanism class and may carry better formulary placement on some Utah Medicaid managed care plans [15].

If a PA is denied, Utah law gives patients the right to an internal appeal within 30 days and an independent external review if the internal appeal fails [16]. HealthRX care coordinators prepare appeal letters that include the SUNRISE-1 and SUNRISE-2 trial data, AASM guideline language, and the patient's prior treatment history to strengthen the case.

503A Compounding Pharmacies and Lemborexant in Utah

Utah is home to several state-licensed 503A compounding pharmacies. A 503A pharmacy compounds drugs for individual patients based on a valid prescription from a licensed prescriber [17]. Compounded lemborexant is not the same as FDA-approved Dayvigo and lacks the same bioequivalence data. The FDA does not permit compounding of commercially available drug products unless the patient has a documented allergy to an excipient in the commercial formulation or another patient-specific medical need [17].

In practical terms, most Utah patients will use the commercially manufactured Dayvigo tablet rather than a compounded form. The 503A pathway exists primarily for patients who, for instance, need a dose form not commercially available (e.g., a liquid suspension for dysphagia) or who have a documented allergy to an inactive ingredient in the Eisai tablet.

Pharmacists at Utah-licensed 503A facilities must hold a valid Utah pharmacy license, and any compounded product must be dispensed pursuant to a patient-specific prescription. Interstate shipping of compounded Schedule IV substances from Utah to another state requires the receiving state's pharmacy board to recognize the dispensing pharmacy's license [17].

Clinical Considerations: Who Benefits Most From Lemborexant

Not every insomnia patient is a good candidate for lemborexant. The drug's profile fits best in specific clinical situations.

Older adults (age 65 and above) represent a population where orexin antagonists offer a meaningful safety margin over benzodiazepines. A 2020 post-hoc analysis of SUNRISE-1 data found that lemborexant 5 mg and 10 mg each significantly improved wake after sleep onset (WASO) in subjects aged 65 and above without the next-morning balance impairment seen with zolpidem extended-release [18]. The American Geriatrics Society Beers Criteria (2023 update) lists benzodiazepines and Z-drugs as medications to avoid in older adults due to fall risk, while orexin antagonists are not included in the avoid list [19].

Patients with comorbid anxiety or depression and insomnia also warrant consideration. Because lemborexant does not potentiate GABA-A receptors, it does not carry the anxiolytic cross-tolerance concern seen with benzodiazepines. A published case series described sustained sleep improvement in patients with generalized anxiety disorder who were already receiving an SSRI, with no pharmacokinetic interaction reported [20].

Patients with a personal or family history of substance use disorder may prefer an orexin antagonist over a Z-drug or benzodiazepine. The abuse potential data from the SUNRISE program showed that lemborexant produced subjective drug liking scores similar to suvorexant and significantly lower than triazolam on validated visual analogue scales [4].

Lemborexant is not appropriate for every patient. Those with severe hepatic impairment (Child-Pugh C) should avoid it, as AUC increases approximately 4-fold vs. subjects with normal hepatic function [2]. Patients who must remain alert during nighttime hours (on-call workers, caregivers) should weigh next-morning residual sedation risk and plan for at least 7 hours of sleep time before driving [2].

Comparing Lemborexant to Other Utah-Available Insomnia Medications

Utah providers prescribe a range of insomnia medications. Knowing where lemborexant fits helps patients have a more productive conversation with their prescriber.

Zolpidem (Ambien, generic): The most commonly prescribed sleep aid in the United States. Zolpidem works via GABA-A enhancement. The FDA required a halving of recommended doses for women in 2013 due to next-morning impairment data [21]. A 2019 Cochrane review of zolpidem (44 trials, N = 4,378) found modest short-term efficacy but noted significant dependence risk with long-term use [22]. Zolpidem is Schedule IV, generic, and inexpensive, making it the first-line choice for most payers.

Eszopiclone (Lunesta): Also a GABA-A agent, Schedule IV. Unique in that the FDA label supports use longer than 4 weeks without a re-evaluation requirement, which was historically unusual for sleep drugs [23]. Generic eszopiclone is available and costs significantly less than branded Dayvigo.

Suvorexant (Belsomra): The first FDA-approved dual orexin receptor antagonist, approved in 2014, mechanistically similar to lemborexant [24]. Head-to-head data from SUNRISE-1 showed lemborexant 10 mg produced statistically superior sleep efficiency on polysomnography vs. suvorexant 20 mg at week 1 (P<0.05) [3].

Trazodone (off-label): Widely used off-label at low doses (25 to 100 mg) for insomnia. Not scheduled. No FDA approval for insomnia. Its evidence base is thin but its cost is near zero. Many Utah payers require a trazodone trial before approving Dayvigo.

Doxepin (Silenor): FDA-approved at 3 mg and 6 mg for insomnia characterized by difficulty with sleep maintenance. A tricyclic antidepressant at sub-antidepressant doses. Not scheduled. Minimal next-morning impairment at approved doses [25].

CBT-I (Cognitive Behavioral Therapy for Insomnia): Not a drug, but the AASM's first-line recommendation. A 2015 meta-analysis in Annals of Internal Medicine (N = 1,162 across 37 RCTs) found CBT-I produced a mean sleep efficiency improvement of 9.9 percentage points and sustained effects at 12-month follow-up without the safety concerns of pharmacotherapy [26].

Using HealthRX to Get Dayvigo Online in Utah

HealthRX operates as a telehealth platform with Utah-licensed clinicians who can evaluate, prescribe, and coordinate pharmacy delivery of Dayvigo for eligible patients. The process at HealthRX runs as follows.

Patients complete an asynchronous intake form covering sleep history, Epworth Sleepiness Scale, prior medications, current drug list, relevant comorbidities, and consent for telehealth services. A Utah-licensed provider reviews the intake and schedules a synchronous video visit, typically within 24 to 48 hours of intake submission. During the video visit, the provider conducts a focused history and mental status assessment, confirms absence of contraindications, and discusses goals, expectations, and risks including next-morning driving impairment.

If lemborexant is appropriate, the provider transmits the electronic controlled substance prescription to the patient's preferred Utah pharmacy. HealthRX care coordinators then initiate the PA process with the patient's insurer if required, using a standardized PA package that includes the AASM guideline citation, SUNRISE trial data, and the patient's documented prior treatment history.

For patients paying cash, HealthRX provides a coupon code compatible with GoodRx pricing. Follow-up visits are scheduled at 4 weeks to assess response and tolerability, with dose titration from 5 mg to 10 mg if the lower dose produces insufficient sleep improvement.

Drug Interactions and Safety Checklist for Utah Patients

Before a Utah provider prescribes lemborexant, a medication reconciliation review checks for the following interactions [2] [27]:

Strong CYP3A4 inhibitors (azole antifungals such as ketoconazole, itraconazole; macrolide antibiotics such as clarithromycin; HIV protease inhibitors) increase lemborexant exposure and are a contraindication or require dose reduction to 5 mg maximum [2].

Strong and moderate CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) decrease lemborexant plasma concentrations and should prompt the prescriber to consider an alternative agent, as efficacy may be significantly reduced [2].

CNS depressants including opioids, alcohol, benzodiazepines, and first-generation antihistamines add to sedative burden. The FDA label includes a specific warning that patients should not take lemborexant with alcohol and should use caution with other CNS depressants [2].

Digoxin is a P-glycoprotein substrate. Lemborexant is a P-glycoprotein inhibitor at clinical doses. Co-administration may increase digoxin AUC by approximately 40%, warranting digoxin level monitoring [2].

Patients over age 65 should begin at 5 mg and only increase to 10 mg if the lower dose is well-tolerated and insufficient after at least 7 days of use [19].